FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.4  |  FHIR Version n/a  User: [n/a]

1495581000168106: List of Medicines for Brand Consideration reference set (foundation metadata concept)


Status: current, Primitive. Date: 30-Sep 2020. Module: Third party reference set module

Descriptions:

Id Description Lang Type Status Case? Module
4462321000168116 List of Medicines for Brand Consideration reference set (foundation metadata concept) en Fully specified name Active Initial character case insensitive Third party reference set module
4462331000168118 List of Medicines for Brand Consideration reference set en Synonym Active Initial character case insensitive Third party reference set module
4462411000168119 List of Medicines for Brand Consideration (LMBC) reference set en Synonym Active Initial character case insensitive Third party reference set module
4462641000168118 <p>Supports the identification of AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC) that forms part of the Active Ingredient Prescribing initiative. Under the <i>National Health (Pharmaceutical Benefits) Regulations 2017</i>, the <i>Repatriation Pharmaceutical Benefits Scheme Instrument 2013</i> and <i>MRCA Pharmaceutical Benefits Scheme Instrument 2013</i>, all PBS and RPBS prescriptions must be prepared by active ingredient, the brand may additionally be identified if a prescriber considers it necessary. The LMBC supports prescribers' decision-making regarding the inclusion of brand on a prescription.</p><p>This reference set can be used by prescribing software vendors to identify medications for brand consideration to meet Active Ingredient Prescribing requirements.</p><p><b>Target Client:&nbsp;</b>This reference set was developed by the National Clinical Terminology Service for the Australian Government Department of Health and Aged Care to support the Active Ingredient Prescribing initiative, and can be used by developers to assist with the requirements.</p> en Definition Active Case sensitive Third party reference set module


1324 members. Search Members:

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
List of Medicines for Brand Consideration reference set Is a Reference sets for Medications true Inferred relationship Some
List of Medicines for Brand Consideration reference set Is a Simple type reference set true Inferred relationship Some
List of Medicines for Brand Consideration reference set Developed by Australian Government Department of Health and Aged Care true Inferred relationship Some 1570063879

Members
insulin glargine 300 units/mL injection, 3 x 3 mL pen devices
insulin glargine 300 international units / 1 mL injection, 5 x 1.5 mL pen devices (medicinal product pack)
insulin glargine 300 units/mL injection, 6 x 3 mL pen devices
insulin glargine 300 units/mL injection, 9 x 3 mL pen devices
insulin glulisine 100 units/mL injection, 1 x 10 mL vial
insulin glulisine 100 units/mL injection, 3 mL pen device
insulin glulisine 100 units/mL injection, 3 mL pen device
insulin glulisine 100 units/mL injection, 5 x 3 mL cartridges
insulin glulisine 100 units/mL injection, 5 x 3 mL pen devices
insulin glulisine 100 units/mL injection, cartridge
insulin glulisine 100 international units / 1 mL injection, vial (medicinal product unit of use)
insulin isophane bovine 100 units/mL injection, 1 x 10 mL vial
insulin isophane bovine 100 units/mL injection, vial
insulin isophane human 100 units/mL injection, 1 x 10 mL vial
insulin isophane human 100 units/mL injection, 3 mL pen device
insulin isophane human 100 units/mL injection, 5 x 3 mL cartridges
insulin isophane human 100 units/mL injection, 5 x 3 mL pen devices
insulin isophane human 100 units/mL injection, cartridge
insulin isophane human 100 units/mL injection, vial
insulin neutral human 50 units/mL + insulin isophane human 50 units/mL injection, 1 x 10 mL vial
insulin neutral human 50 units/mL + insulin isophane human 50 units/mL injection, 5 x 3 mL cartridges
insulin neutral human 50 units/mL + insulin isophane human 50 units/mL injection, cartridge
insulin neutral human 50 units/mL + insulin isophane human 50 units/mL injection, vial
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 10 mL vial
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 3 mL cartridge
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 3 mL pen device
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 5 x 3 mL cartridges
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 5 x 3 mL pen devices
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, 5 x 3 mL syringes
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, syringe
insulin neutral human 30 units/mL + insulin isophane human 70 units/mL injection, vial
insulin neutral human 20 units/mL + insulin isophane human 80 units/mL injection, 5 x 3 mL cartridges
insulin neutral human 20 units/mL + insulin isophane human 80 units/mL injection, cartridge
insulin isophane porcine 100 units/mL injection, 3 mL cartridge
insulin isophane porcine 100 units/mL injection, 5 x 3 mL cartridges
insulin lispro 100 units/mL injection, 1 x 10 mL vial
insulin lispro 100 units/mL injection, 3 mL pen device
insulin lispro 100 units/mL injection, 5 x 3 mL cartridges
insulin lispro 100 units/mL injection, 5 x 3 mL pen devices
insulin lispro 100 units/mL injection, cartridge
insulin lispro 100 units/mL injection, vial
insulin lispro 200 units/mL injection, 2 x 3 mL pen devices
insulin lispro 200 units/mL injection, 3 mL pen device
insulin lispro 200 units/mL injection, 5 x 3 mL pen devices
insulin lispro 25 units/mL + insulin lispro protamine 75 units/mL injection, 3 mL pen device
insulin lispro 25 units/mL + insulin lispro protamine 75 units/mL injection, 5 x 3 mL cartridges
insulin lispro 25 units/mL + insulin lispro protamine 75 units/mL injection, 5 x 3 mL pen devices
insulin lispro 25 units/mL + insulin lispro protamine 75 units/mL injection, cartridge
insulin lispro 50 units/mL + insulin lispro protamine 50 units/mL injection, 3 mL pen device
insulin lispro 50 units/mL + insulin lispro protamine 50 units/mL injection, 5 x 3 mL cartridges
insulin lispro 50 units/mL + insulin lispro protamine 50 units/mL injection, 5 x 3 mL pen devices
insulin lispro 50 units/mL + insulin lispro protamine 50 units/mL injection, cartridge
insulin neutral bovine 100 units/mL injection, 1 x 10 mL vial
insulin neutral bovine 100 units/mL injection, vial
insulin neutral human 100 units/mL injection, 1 x 10 mL vial
insulin neutral human 100 units/mL injection, syringe
insulin neutral human 100 units/mL injection, 5 x 3 mL cartridges
insulin neutral human 100 units/mL injection, 5 x 3 mL syringes
insulin neutral human 100 units/mL injection, cartridge
insulin neutral human 100 units/mL injection, vial
insulin neutral porcine 100 units/mL injection, 3 mL cartridge
insulin neutral porcine 100 units/mL injection, 5 x 3 mL cartridges
interferon beta-1a 6 million units (30 microgram)/0.5 mL injection, syringe
interferon beta-1a 6 million units (30 microgram)/0.5 mL injection, 4 x 0.5 mL syringes
interferon beta-1a 6 million units (30 microgram) injection, vial
interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, pen device
interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, syringe
interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, 0.5 mL pen device
interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, 1 x 0.5 mL syringe
interferon beta-1a 44 microgram / 0.5 mL injection, 12 x 0.5 mL pen devices (medicinal product pack)
interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, 12 x 0.5 mL syringes
interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, 3 x 0.5 mL pen devices
interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, 3 x 0.5 mL syringes
iron (as ferric carboxymaltose) 1 g/20 mL injection, 20 mL vial
iron (as ferric carboxymaltose) 1 g/20 mL injection, vial
iron (as ferric carboxymaltose) 100 mg/2 mL injection, 2 mL vial
iron (as ferric carboxymaltose) 100 mg/2 mL injection, vial
iron (as ferric carboxymaltose) 100 mg/2 mL injection, 5 x 2 mL vials
iron (as ferric carboxymaltose) 500 mg/10 mL injection, 10 mL vial
iron (as ferric carboxymaltose) 500 mg/10 mL injection, vial
iron (as ferric carboxymaltose) 500 mg/10 mL injection, 5 x 10 mL vials
iron (as ferric derisomaltose) 1 g/10 mL injection, 10 mL vial
iron (as ferric derisomaltose) 1 g/10 mL injection, vial
iron (as ferric derisomaltose) 1 g/10 mL injection, 2 x 10 mL vials
iron (as ferric derisomaltose) 1 g/10 mL injection, 5 x 10 mL vials
iron (as ferric derisomaltose) 500 mg/5 mL injection, 5 mL vial
iron (as ferric derisomaltose) 500 mg/5 mL injection, 2 x 5 mL vials
iron (as ferric derisomaltose) 500 mg/5 mL injection, vial
iron (as ferric derisomaltose) 500 mg/5 mL injection, 5 x 5 mL vials
iron (as polymaltose) 100 mg/2 mL injection, ampoule
iron (as polymaltose) 100 mg/2 mL injection, 5 x 2 mL ampoules
iron (as sucrose) 100 mg/5 mL injection, ampoule
iron (as sucrose) 100 mg/5 mL injection, 5 x 5 mL ampoules
itraconazole 100 mg capsule
itraconazole 100 mg capsule, 15
itraconazole 100 mg capsule, 28
itraconazole 100 mg capsule, 4
itraconazole 100 mg capsule, 6
itraconazole 100 mg capsule, 60
itraconazole 50 mg capsule
itraconazole 50 mg capsule, 15

Start Previous Page 9 of 14 Next End


Reference Sets

Australian dialect reference set

Reference set descriptor

Back to Start